PCRX
HealthcarePacira BioSciences, Inc.
$25.10
+$0.64 (+2.62%)
Jan 5, 2026
Price History (1Y)
Analysis
Pacira BioSciences, Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry. With a market capitalization of $1.13 billion and revenue of $716.79 million, it is a significant player in its sector. The company employs approximately 788 individuals. From a financial health perspective, Pacira BioSciences has demonstrated profitability with gross margin, operating margin, and profit margin rates of 65.7%, 7.3%, and 3.0% respectively. The company's returns on equity (ROE) and return on assets (ROA) are both 2.9%. Its balance sheet shows a debt-to-equity ratio of 58.48 and a current ratio of 5.26, with cash reserves totaling $246.33 million against debt of $425.31 million. In terms of valuation context, Pacira BioSciences has a price-to-earnings (P/E) ratio of 52.29 and a forward P/E of 7.37, indicating a significant multiple on past earnings but relatively low expectations for future growth. The company's revenue growth rate is 6.5% year-over-year, while its earnings growth rate is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Visit website →Key Statistics
- Market Cap
- $1.13B
- P/E Ratio
- 52.29
- 52-Week High
- $27.64
- 52-Week Low
- $18.18
- Avg Volume
- 727.04K
- Beta
- 0.23
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 788